[FLASH SALE] Global Database of Cell and Gene Therapy CDMOs, 2026

Description

The world’s only publicly available database of all known Cell and Gene Therapy (CGT) CDMOs worldwide.

Because this database was recently updated, for a limited time, you can claim it for an unusual $150 off.

Among cell and gene therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise. Benefits of partnering with a cell or gene therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. This database features companies who specialize in manufacturing and clinical trial support specifically for cell and gene therapies (CGT).

In addition to industry giants such as Minaris Advanced Therapies (formed through the merger of Minaris Regenerative Medicine and WuXi Advanced Therapies), Lonza, RoslinCT, and Novo Holdings (which acquired Catalent),  the cell and gene therapy marketplace is also supported by a range of specialized CDMOs focused on this sector.

For example, FUJIFILM Cellular Dynamics opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products. Similarly, Helixmith, a biotech company with an extensive gene therapy pipeline and a CAR-T program targeting solid tumors, expanded into CDMO services for early-stage CAR-T developers.

In other news, ThermoGenesis launched CDMO services with expertise in CAR-T cells, T cell receptor (TCR), tumor-infiltrating leukocytes (TILs), natural killer cells (NKs), iPSCs, and MSCs. Similarly, Esco Aster is a global CDMO that is supporting the rapidly emerging field of EVs, producing both regenerative medical-grade naïve extracellular vesicles (MNEVs) and Continuously Engineered Exosomes/Extracellular Vesicles CEEVs (CEEVs).

Likewise, Anemocyte is the first BMO (Biotech Manufacturing Organization) in the field of cell and gene therapies. In addition to building 2000 sq. meters of GMP and GMP-compliant facilities for the production of ATMPs, its FLYn’ICE project is using drones equipped with cryogenic pods to achieve temperature controlled transit of cell and gene therapies.

RoslinCT, a cell and gene therapy CDMO based in the UK, and Lykan Bioscience, a CDMO focused on cellular therapeutics in Hopkinton, MA, merged to form an international CDMO specializing in advanced therapeutics—with a specialty in gene editing and iPSC capabilities.

Of course, there have been hefty M&A deals inked within the cell and gene therapy CDMO sector as well. For example, industry behemoth Thermo Fisher Scientific snagged Brammer Bio for an astonishing $1.7B, while Catalent acquired Paragon Bioservices for an impressive $1.2B and MaSTherCell for $315 million.

Hitachi Chemical Advanced Therapeutics Solutions (HCATS), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. Regenerative Medicine combined to operate under the joint name of Minaris Regenerative Medicine, which subsequently merged with WuXi Advanced Therapies in early 2025 to become Minaris Advanced Therapies.

Meanwhile Charles River Laboratories (CRL) acquired Cognate BioServices for a hefty price tag of $875 million. Ascend Gene & Cell Therapies also raised an impressive $132.5M to launch itself as a CDMO specializing in AVV-based gene therapies.

In late 2023, Bayer opened a $250M cell therapy manufacturing facility to advance regenerative medicines on a global scale. Around the same time, Ajinomoto Co. acquired CDMO Forge Biologics for an astounding $620 million to enhance its Bio-Pharma Services business. In 2024, EXO Biologics launched its wholly owned subsidiary, ExoXpert^TM, as a CDMO specializing in exosomes. ExoXpert offers a MSC-based exosome manufacturing platform used in European clinical trials.

Novo Holdings acquired the global CDMO Catalent for a staggering $16.5 billion in enterprise value, while Avid Biosciences was snagged by private equity companies in an all-cash transaction worth an breathtaking $1.1 billion.

Database of Cell and Gene Therapy CDMOs

In recent years, CDMOs to advance transformational regenerative medicines have proliferated, with the goal to break the current bottlenecks constraining the production of these novel therapeutics. When you claim this database, you can immediately know the identities of all known cell and gene therapy CDMOs worldwide.

It takes our analysts a vast amount of research to uncover these cell and gene therapy (CGT) CDMOs from across the globe and requires the translation of websites across numerous languages. Thankfully, we have a talented, multilingual team who is up to the task. Because we continuously update this database to reflect new competitors entering the marketplace, we are confident that you will find it to be invaluable resource.

As you can imagine, the quality of this database would not be possible without the past 19 years of following this industry and developing proprietary datasets (to which AI does not have access).

These insights exist because they are built on nearly two decades of granular tracking, interviews, proprietary datasets, and daily monitoring.

If you want immediate and actionable insights from a trusted, U.S. based provider that specializes exclusively in cell therapy market insights, then this database is for you.

If you are a cell therapy developer, you can use this database to identify potential manufacturing partners. If you are a contract manufacturer, you can use it to identify the depth and breadth of your market competition.

The database features:

1. Name of Company
2. Type of CMO/CDMO
3. City and  State
4. Country
5. Company Website
6. Company Phone
7. Email Contact
8. Description of Cell and Gene Therapy CDMO Services

Use it to:

1) Compare companies capable of manufacturing your cell or gene therapy product
2) Identify all known market competitors within the cell therapy CDMO industry
3) Identify new market entrants offering CDMO services
4) Spot countries with a high number of cell and gene therapy CDMOs (“geographic hotspots”)
5) Identify companies that specialize in the production of specific types of CGT products (“niche” CDMOs)

When you check out below, your product will be delivered instantly as an Excel download. Of course, your investment is backed by a Greater than 100% Money Back Guarantee. If you have questions about this product, please email [email protected] for a quick response.

To view License Descriptions, please click here.

Format: Excel File (Delivered Instantly)
No. of Companies: 137 Total
Last Updated: April 18, 2026

For a limited time, you can claim this database for an unusual $150 off. Remember to act fast, because this offer expires soon.

*As you can imagine, we couldn’t possibly fit all of the company logos into a single feature image, so if you company is not included in the image above, it is still likely to be included within this database.